| DB ID | MyCo_1837 |
| Title | Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production |
| Year | 1996 |
| PMID | 8706323 |
| Fungal Diseases involved | Chronic mucocutaneous candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | Ethical approval was granted by the Newcastle Ethical Committee and informed consent of patients or parents was obtained in all cases. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Plasma |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-4 |
| Biomarker Full Name | Interleukin-4 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Ten patients and 20 age- and sex-matched healthy controls were studied. |
| Cohort No. | 10 Patients and 20 control |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Chronic mucocutaneous candidiasis (CMC) is a primary immuno-deficiency disease presenting with debilitating, persistent and refractory infections with the opportunistic yeast Candida albicans. Infections vary from mild to lethal, are characteristically localized to the skin, mucous membranes and/or nails, and as a rule do not progress to disseminated disease or sepsis. They are often associated with thymoma, polyendocrinopathies and other phenomena thought to be autoimmune in nature. Onset is fre- quently in childhood but can be in adult life; the disease may be sporadic or show familial association. The underlying immune defect is poorly understood, although it has been appreciated that mucocutaneous infections with Candida other than in CMC frequently accompany impairment of T cell-mediated immunity (HIV, Di George syndrome, etc.). Studies performed over a decade ago suggested that the crucial defect is selective impair-ment of cell-mediated immunity, resulting in the inability to clear Candida infection. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (AMS Biotechnology, Phar-mingen and R&D, respectively), |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
